{"id":26287,"date":"2024-11-21T09:39:25","date_gmt":"2024-11-21T08:39:25","guid":{"rendered":"https:\/\/mabdesign.fr\/?p=26287"},"modified":"2024-11-21T09:39:25","modified_gmt":"2024-11-21T08:39:25","slug":"osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/","title":{"rendered":"Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836"},"content":{"rendered":"\n<p>Lyon, France\u00a0<strong>\u2013 November 14, 2024\u00a0\u2013<\/strong> <a href=\"https:\/\/osivax.com\/\">Osivax<\/a>, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses,\u00a0today announced that the first participant has been vaccinated\u00a0in a Phase 2a clinical trial (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06582277?term=osivax&amp;rank=1\" target=\"_blank\" rel=\"noreferrer noopener\">NCT06582277<\/a>) evaluating OVX836, its broad-spectrum\u00a0influenza vaccine candidate as a booster in participants previously administered\u00a0with OVX836.<\/p>\n\n\n\n<p>Based on the encouraging data gathered so far, Osivax launched this study to\u00a0further assess the safety and immunogenicity of a booster dose of OVX836. The\u00a0booster dose will be administered to participants who were vaccinated three to five\u00a0years ago in earlier Osivax studies at the same clinical site. The study is taking\u00a0place at the Center for Vaccinology (CEVAC) at Ghent University Hospital. <a href=\"https:\/\/osivax.com\/first-participant-in-ph2a-booster-trial-flu-ovx836\/\">To know more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses,\u00a0today announced that the first participant has been vaccinated\u00a0in a Phase 2a clinical trial (NCT06582277) evaluating OVX836, its broad-spectrum\u00a0influenza vaccine candidate as a booster in participants previously administered\u00a0with OVX836.<\/p>\n","protected":false},"author":3,"featured_media":7695,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32],"tags":[],"class_list":["post-26287","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-our-members"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836 - MabDesign<\/title>\n<meta name=\"description\" content=\"Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses,\u00a0today announced that the first participant has been vaccinated\u00a0in a Phase 2a clinical trial (NCT06582277) evaluating OVX836, its broad-spectrum\u00a0influenza vaccine candidate as a booster in participants previously administered\u00a0with OVX836. Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses,\u00a0today announced that the first participant has been vaccinated\u00a0in a Phase 2a clinical trial (NCT06582277) evaluating OVX836, its broad-spectrum\u00a0influenza vaccine candidate as a booster in participants previously administered\u00a0with OVX836.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836 - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses,\u00a0today announced that the first participant has been vaccinated\u00a0in a Phase 2a clinical trial (NCT06582277) evaluating OVX836, its broad-spectrum\u00a0influenza vaccine candidate as a booster in participants previously administered\u00a0with OVX836. Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses,\u00a0today announced that the first participant has been vaccinated\u00a0in a Phase 2a clinical trial (NCT06582277) evaluating OVX836, its broad-spectrum\u00a0influenza vaccine candidate as a booster in participants previously administered\u00a0with OVX836.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-21T08:39:25+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"152\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Laure Delhon\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Laure Delhon\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/\"},\"author\":{\"name\":\"Laure Delhon\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39\"},\"headline\":\"Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836\",\"datePublished\":\"2024-11-21T08:39:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/\"},\"wordCount\":134,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg\",\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/\",\"name\":\"Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836 - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg\",\"datePublished\":\"2024-11-21T08:39:25+00:00\",\"description\":\"Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses,\u00a0today announced that the first participant has been vaccinated\u00a0in a Phase 2a clinical trial (NCT06582277) evaluating OVX836, its broad-spectrum\u00a0influenza vaccine candidate as a booster in participants previously administered\u00a0with OVX836. Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses,\u00a0today announced that the first participant has been vaccinated\u00a0in a Phase 2a clinical trial (NCT06582277) evaluating OVX836, its broad-spectrum\u00a0influenza vaccine candidate as a booster in participants previously administered\u00a0with OVX836.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg\",\"width\":600,\"height\":152},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39\",\"name\":\"Laure Delhon\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g\",\"caption\":\"Laure Delhon\"},\"url\":\"https:\/\/mabdesign.fr\/en\/author\/laure-delhonmabdesign-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836 - MabDesign","description":"Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses,\u00a0today announced that the first participant has been vaccinated\u00a0in a Phase 2a clinical trial (NCT06582277) evaluating OVX836, its broad-spectrum\u00a0influenza vaccine candidate as a booster in participants previously administered\u00a0with OVX836. Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses,\u00a0today announced that the first participant has been vaccinated\u00a0in a Phase 2a clinical trial (NCT06582277) evaluating OVX836, its broad-spectrum\u00a0influenza vaccine candidate as a booster in participants previously administered\u00a0with OVX836.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/","og_locale":"en_US","og_type":"article","og_title":"Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836 - MabDesign","og_description":"Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses,\u00a0today announced that the first participant has been vaccinated\u00a0in a Phase 2a clinical trial (NCT06582277) evaluating OVX836, its broad-spectrum\u00a0influenza vaccine candidate as a booster in participants previously administered\u00a0with OVX836. Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses,\u00a0today announced that the first participant has been vaccinated\u00a0in a Phase 2a clinical trial (NCT06582277) evaluating OVX836, its broad-spectrum\u00a0influenza vaccine candidate as a booster in participants previously administered\u00a0with OVX836.","og_url":"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/","og_site_name":"MabDesign","article_published_time":"2024-11-21T08:39:25+00:00","og_image":[{"width":600,"height":152,"url":"http:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg","type":"image\/jpeg"}],"author":"Laure Delhon","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"Laure Delhon","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/"},"author":{"name":"Laure Delhon","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39"},"headline":"Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836","datePublished":"2024-11-21T08:39:25+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/"},"wordCount":134,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg","articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/","url":"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/","name":"Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836 - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg","datePublished":"2024-11-21T08:39:25+00:00","description":"Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses,\u00a0today announced that the first participant has been vaccinated\u00a0in a Phase 2a clinical trial (NCT06582277) evaluating OVX836, its broad-spectrum\u00a0influenza vaccine candidate as a booster in participants previously administered\u00a0with OVX836. Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses,\u00a0today announced that the first participant has been vaccinated\u00a0in a Phase 2a clinical trial (NCT06582277) evaluating OVX836, its broad-spectrum\u00a0influenza vaccine candidate as a booster in participants previously administered\u00a0with OVX836.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2023\/09\/OSIVAX-logo.jpg","width":600,"height":152},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza-vaccine-candidate-ovx836\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39","name":"Laure Delhon","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g","caption":"Laure Delhon"},"url":"https:\/\/mabdesign.fr\/en\/author\/laure-delhonmabdesign-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/26287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=26287"}],"version-history":[{"count":1,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/26287\/revisions"}],"predecessor-version":[{"id":26288,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/26287\/revisions\/26288"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/7695"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=26287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=26287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=26287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}